Eisai Co., Ltd., a pharmaceutical company based in Tokyo has been found its place yet again in the Global 100 Most Sustainable Corporations in the World (Global 100) list. This marks the tenth time Eisai has achieved this recognition. The Global 100 list is assembled and published by Corporate Knights, Inc., a Canadian media and investment advisory company. This ranking […]
Eisai
Eisai, Nuvation Bio Expand Licensing Deal for Taletrectinib to Europe, Other Countries
Eisai Co., Ltd. and Nuvation Bio Inc. have announced a long-term exclusive license and collaboration agreement for the drug taletrectinib. Already approved for advanced non-small cell lung cancer (NSCLC) in the U.S, China, and Japan, under the new agreement, Eisai will now have exclusive development, registration and commercialization rights for taletrectinib, in Europe and several other regions. The territories include […]
